Option Traders Are Pricing a Nearly 22% Move in Tilray Stock Before the End of 2025. Should You Buy, Sell, or Hold TLRY Here?

Tilray (TLRY) shares soared about 30% today after President Donald Trump said he’s “strongly” considering an executive order that will reclassify cannabis as a Schedule III drug. The expected mandate will also authorize a pilot program that will enable seniors to access cannabis products under Medicare coverage, according to media reports on Tuesday. More News from Barchart Following today’s surge, Tilray stock is up more than 100% versus its recent low set on Dec. 4. www.barchart.com What Cannabis R ...